POSTER PRESENTATION

Impact of carboplatin and cisplatin shortages on treatment patterns in patients with metastatic solid tumors

Author affiliations: Flatiron Health

In 2023, the US faced critical shortages of essential chemotherapy drugs, cisplatin (CP) and carboplatin (CB), prompting concerns about potential rationing and the search for alternative treatments in oncology. However, real-time data on how these shortages affected patient care has been limited and difficult to obtain. This study employed machine-learning techniques to examine how these shortages impacted CP and CB usage across seven cancer types. Using real-world data from US oncology practices, the study aimed to understand their effect on treatment decisions and practice patterns during the shortage period.

POSTER PRESENTATION

Real-world ctDNA testing patterns, associated biomarkers and sites of metastasis in early stage colorectal cancer

Author affiliations: Flatiron Health

Recognizing the potential of ctDNA in early-stage CRC highlights its significance as a prognostic and predictive tool. However, further work is needed to better understand its clinical application, especially in the real-world setting. Using data from Flatiron Health's nationwide electronic health record (EHR) database, this study aimed to investigate ctDNA testing trends in routine care along with its correlation to other biomarkers and sites of metastasis in early-stage CRC patients. This research represents the largest investigation of ctDNA testing in early-stage CRC, offering valuable insights into the potential for biomarker-informed disease monitoring and treatment strategies.

POSTER PRESENTATION

Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients with HR+/HER2- metastatic breast cancer in the US

Author affiliations: AstraZeneca, Flatiron Health, and MD Anderson Cancer Center

Biomarkers are essential for guiding treatment in metastatic breast cancer (mBC). Next-generation sequencing (NGS) is critical for identifying important biomarkers such as PIK3CA, AKT1, and PTEN. The recent FDA approval of capivasertib highlights the importance of understanding these genetic changes. This study investigates how often the tumors of patients with HR+/HER2- mBC are tested for alterations in these genes, and how often alterations are present.

POSTER PRESENTATION

Racial/ethnic inequities in care for patients with advanced endometrial cancer: what’s structural racism and social determinants of health got to do with it?

Author affiliations: Flatiron Health

Structural racism and social determinants of health (SDOH) contribute to inequities in endometrial cancer care, but their precise impact is not fully understood. This study investigates their role in racial/ethnic inequities among patients with advanced endometrial cancer (aEC), focusing on treatment initiation, biomarker testing, and clinical trial participation. The findings underscore the importance of addressing structural and social drivers to promote trial diversity and achieve equity in outcomes.

POSTER PRESENTATION

The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

Author affiliations: Flatiron Health, GSK, University of Virginia

Evidence from phase III trials show that adding bevacizumab to first-line platinum-based chemotherapy regimens for the treatment of epithelial ovarian cancer improves progression-free survival for most patients. However, the overall survival benefit may be limited to those with high-risk clinical factors. This study uses real-world data to identify which patients benefit most from the addition of bevacizumab to a frontline chemotherapy regimen based on the presence of high-risk clinical factors. By validating trial findings, it offers insights into tailoring ovarian cancer treatment strategies based on individual risk profiles.

POSTER PRESENTATION

Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients with advanced endometrial cancer, 2018-2023

Author affiliations: AstraZeneca, Flatiron Health, NYU Langone Health, Washington University School of Medicine

In the past decade, significant strides have been made in treating advanced endometrial cancer (aEC), with the introduction of newer therapies in both first-line (1L) and second-line (2L) settings. Molecular profiling, especially MMR/MSI testing, has become essential for treatment decisions. However, there's still a lack of real-world evidence on the changing treatment landscape. This study assesses how molecular profiling is being adopted and the resulting treatment trends and patient outcomes in aEC, all critical to improving our understanding of aEC in order to ensure better access to tailored treatments.

ONLINE PUBLICATION

Utility of automated data transfer for cancer clinical trials

Author affiliations: Flatiron Health, MD Anderson Cancer Center, Washington University in St. Louis

The growing demand for data in cancer trials burdens staff with manual entry into electronic data capture (EDC) systems, causing inefficiencies and errors. Implementing software for automated data transfer from EHR to EDC offers a solution. This study assesses the impact of such software across multiple multi-center Phase 1 cancer trials, revealing its potential to streamline processes and enhance data accuracy.

ONLINE PUBLICATION

Characterization of cancer clinical trials in the community setting

Author affiliations: Association of Community Cancer Centers, City of Hope, Flatiron Health, Penn Medicine Lancaster General Health

Expanding clinical trials to community oncology sites is crucial for enrollment, generalizability, and equitable care access. This study explores the characteristics of cancer trials open across a network of US community practices, to inform sponsors and sites about the types of studies most successful in the community setting. It highlights the robust and diverse trial portfolios at community practices, and emphasizes their pivotal role to ensure access to research and improved patient outcomes.

ONLINE PUBLICATION

Treatment inequities in patients with metastatic non-small cell lung cancer harboring actionable driver oncogenes in the first-line setting

Author affiliations: Flatiron Health, Foundation Medicine, Genentech, Mary Bird Perkins Cancer Center, New York Cancer and Blood Specialists, OneOncology, Tennessee Oncology, and West Cancer Center and Research Institute

Metastatic non-small cell lung cancer (mNSCLC) is predominantly treated with targeted therapies, particularly benefiting metastatic NSCLC patients with actionable driver oncogenes like ALK, BRAF, EGFR, MET, NTRK, RET, and ROS-1. This study investigates whether all mNSCLC patients with these mutations receive equitable access to recommended first-line targeted treatments in US clinical practices, emphasizing the need for fair access to improve healthcare outcomes and equity.